Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10134
mi
from
South Burlington, VT
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10134
mi
from
South Burlington, VT
Click here to add this to my saved trials
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10102
mi
from
Fairfax, VA
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10102
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13964
mi
from
Litchfield Park, AZ
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13964
mi
from
Litchfield Park, AZ
Click here to add this to my saved trials
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10143
mi
from
Riverside, CA
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10143
mi
from
Riverside, CA
Click here to add this to my saved trials
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Savannah, GA
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10552
mi
from
Saint Louis, MO
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10552
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10263
mi
from
Knoxville, TN
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10263
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10119
mi
from
Boerne, TX
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10119
mi
from
Boerne, TX
Click here to add this to my saved trials
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13921
mi
from
Loxahatchee Groves, FL
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13921
mi
from
Loxahatchee Groves, FL
Click here to add this to my saved trials
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10114
mi
from
Brick, NJ
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10114
mi
from
Brick, NJ
Click here to add this to my saved trials
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Oklahoma City, OK
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Birmingham, AL
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10173
mi
from
Bakersfield, CA
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10173
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Huntington Beach, CA
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10106
mi
from
Stockton, CA
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10106
mi
from
Stockton, CA
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10153
mi
from
Aventura, FL
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10153
mi
from
Aventura, FL
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12336
mi
from
Homestead, FL
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12336
mi
from
Homestead, FL
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1345
mi
from
Miami, FL
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1345
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10269
mi
from
Orlando, FL
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10269
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10161
mi
from
Tallahassee, FL
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10161
mi
from
Tallahassee, FL
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Tampa, FL
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13249
mi
from
Buford, GA
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13249
mi
from
Buford, GA
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1367
mi
from
Chicago, IL
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1367
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13202
mi
from
Michigan City, IN
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13202
mi
from
Michigan City, IN
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10070
mi
from
Owensboro, KY
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10070
mi
from
Owensboro, KY
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13191
mi
from
Lafayette, LA
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13191
mi
from
Lafayette, LA
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10138
mi
from
North Dartmouth, MA
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10138
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13258
mi
from
Boys Town, NE
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13258
mi
from
Boys Town, NE
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 14652
mi
from
Ocean City, NJ
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 14652
mi
from
Ocean City, NJ
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1022
mi
from
Lake Success, NY
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1022
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1355
mi
from
New York, NY
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1355
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Cincinnati, OH
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 11
mi
from
Cleveland, OH
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 11
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 12377
mi
from
Edmond, OK
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 12377
mi
from
Edmond, OK
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13218
mi
from
Jenkintown, PA
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13218
mi
from
Jenkintown, PA
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10166
mi
from
Pittsburgh, PA
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10166
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 11119
mi
from
East Providence, RI
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 11119
mi
from
East Providence, RI
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10511
mi
from
Warwick, RI
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10511
mi
from
Warwick, RI
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10263
mi
from
Knoxville, TN
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10263
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13199
mi
from
Corsicana, TX
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13199
mi
from
Corsicana, TX
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Dallas, TX
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10576
mi
from
Provo, UT
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10576
mi
from
Provo, UT
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13207
mi
from
Abingdon, VA
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13207
mi
from
Abingdon, VA
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13257
mi
from
Falls Church, VA
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13257
mi
from
Falls Church, VA
Click here to add this to my saved trials
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 37082
mi
from
Bruxelles,
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 37082
mi
from
Bruxelles,
Click here to add this to my saved trials
Study of Mepolizumab Autoinjector in Asthmatics
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Los Angeles, CA
Study of Mepolizumab Autoinjector in Asthmatics
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Mepolizumab Autoinjector in Asthmatics
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Colorado Springs, CO
Study of Mepolizumab Autoinjector in Asthmatics
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Study of Mepolizumab Autoinjector in Asthmatics
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Aventura, FL
Study of Mepolizumab Autoinjector in Asthmatics
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Aventura, FL
Click here to add this to my saved trials
Study of Mepolizumab Autoinjector in Asthmatics
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Albany, GA
Study of Mepolizumab Autoinjector in Asthmatics
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Albany, GA
Click here to add this to my saved trials
Study of Mepolizumab Autoinjector in Asthmatics
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Saint Louis, MO
Study of Mepolizumab Autoinjector in Asthmatics
An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials